All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub was pleased to speak to Moshe Mittelman, Tel Aviv University, Tel Aviv, IL. We asked, What is the sequence of therapy in myelodysplastic syndromes (MDS)?
Sequence of therapy in myelodysplastic syndromes
Mittelman begins by explaining how the sequence of therapy is dependant on the individual patient's risk classification. Mittelman goes on to discuss response rates for different drugs including lenalidomide and erythroid-stimulating agents. Finally, Mittelman discusses drugs currently under investigation, and using stem cell transplant (SCT) as a possible approach in the future.
Visual abstract | Azacitidine, Lenalidomide and DLI as salvage therapy for MDS, CMML and sAML after allo-HSCT (AZALENA)
Visual abstract: Azacitidine, Lenalidomide and DLI as salvage therapy for MDS, CMML and sAML after allo-HSCT (AZALENA)
Outcomes of long-term survivors after hematopoietic stem cell transplantation
Despite advances in the field of targeted therapies, hematopoietic stem cell transplantation (HSCT) is still an important curative option for a number of hematological and...
Subscribe to get the best content related to MDS delivered to your inbox